Abpro Holdings, Inc Common Stock
About: Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.
Employees: 6
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0% more funds holding
Funds holding: 13 [Q4 2024] → 13 (+0) [Q1 2025]
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
0.03% less ownership
Funds ownership: 3.06% [Q4 2024] → 3.03% (-0.03%) [Q1 2025]
69% less capital invested
Capital invested by funds: $1.99M [Q4 2024] → $616K (-$1.38M) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Maxim Group Jason McCarthy 19% 1-year accuracy 6 / 31 met price target | 1,639%upside $4 | Buy Initiated | 24 Feb 2025 |
Financial journalist opinion



